WO2016093554A3 - 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과 - Google Patents

신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과 Download PDF

Info

Publication number
WO2016093554A3
WO2016093554A3 PCT/KR2015/013150 KR2015013150W WO2016093554A3 WO 2016093554 A3 WO2016093554 A3 WO 2016093554A3 KR 2015013150 W KR2015013150 W KR 2015013150W WO 2016093554 A3 WO2016093554 A3 WO 2016093554A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkoxythieno
pyrazin
piperazine
aryl
novel
Prior art date
Application number
PCT/KR2015/013150
Other languages
English (en)
French (fr)
Other versions
WO2016093554A2 (ko
Inventor
공영대
곽세훈
이은실
Original Assignee
동국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동국대학교 산학협력단 filed Critical 동국대학교 산학협력단
Priority to PL15867145T priority Critical patent/PL3231800T3/pl
Priority to US15/533,076 priority patent/US10059721B2/en
Priority to JP2017530301A priority patent/JP6349464B2/ja
Priority to EP15867145.3A priority patent/EP3231800B1/en
Publication of WO2016093554A2 publication Critical patent/WO2016093554A2/ko
Publication of WO2016093554A3 publication Critical patent/WO2016093554A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

본 발명은 암의 예방 또는 치료에 유용하게 사용할 수 있는, 신규한 4-(아릴)-N-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물에 관한 것이다. 본 발명의 신규한 4-(아릴)-N-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 화합물은 증식성 세포 성장을 효과적으로 억제할 수 있으므로, 암의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2015/013150 2014-12-08 2015-12-03 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과 WO2016093554A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL15867145T PL3231800T3 (pl) 2014-12-08 2015-12-03 Nowa pochodna 4-(arylo) -n-(2-alkoksytieno[3,2-b]pirazyn-3-ylo)-piperazyno-1-karboksyamidu oraz jej działanie antyproliferacyjne
US15/533,076 US10059721B2 (en) 2014-12-08 2015-12-03 Substituted thieno[3,2-b]pyrazines for inhibiting cancer cell proliferation and inducing cancer cell apoptosis
JP2017530301A JP6349464B2 (ja) 2014-12-08 2015-12-03 新規な４−（アリール）−Ｎ−（２−アルコキシチエノ［３，２−ｂ］ピラジン−３−イル）−ピペラジン−１−カルボキサミド誘導体及びその抗増殖効果
EP15867145.3A EP3231800B1 (en) 2014-12-08 2015-12-03 Novel 4-(aryl)-n-(2-alkoxythieno[3,2-b]pyrazin-3-yl)-piperazine-1-carboxamide derivative, and antiproliferative effect thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0175121 2014-12-08
KR20140175121 2014-12-08

Publications (2)

Publication Number Publication Date
WO2016093554A2 WO2016093554A2 (ko) 2016-06-16
WO2016093554A3 true WO2016093554A3 (ko) 2016-10-27

Family

ID=56108326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/013150 WO2016093554A2 (ko) 2014-12-08 2015-12-03 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과

Country Status (7)

Country Link
US (1) US10059721B2 (ko)
EP (1) EP3231800B1 (ko)
JP (1) JP6349464B2 (ko)
KR (1) KR101727412B1 (ko)
HU (1) HUE046316T2 (ko)
PL (1) PL3231800T3 (ko)
WO (1) WO2016093554A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6349464B2 (ja) * 2014-12-08 2018-06-27 ドングク ユニバーシティ インダストリー−アカデミック コーポレイション ファウンデーション 新規な４−（アリール）−Ｎ−（２−アルコキシチエノ［３，２−ｂ］ピラジン−３−イル）−ピペラジン−１−カルボキサミド誘導体及びその抗増殖効果
WO2017213452A1 (ko) * 2016-06-09 2017-12-14 동국대학교 산학협력단 신규한 4-(아릴)-n-(3-알콕시퓨로[2,3-b]피라진-2-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과
KR101872645B1 (ko) 2016-06-09 2018-08-03 동국대학교 산학협력단 신규한 4-(아릴)-N-(3-알콕시퓨로[2,3-b]피라진-2-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과
CN111606920A (zh) * 2020-05-29 2020-09-01 凯美克(上海)医药科技有限公司 一种7-溴噻吩并[2,3-b]吡嗪的合成方法
WO2024205336A1 (ko) * 2023-03-30 2024-10-03 에이치엘비생명과학알앤디 주식회사 튜블린 저해 활성을 갖는 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052001A1 (en) * 1999-03-03 2000-09-08 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
WO2006054830A1 (en) * 2004-11-17 2006-05-26 Rexahn Pharmaceuticals, Inc. 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US8669256B2 (en) * 2010-05-28 2014-03-11 Merck Sharp & Dohme B.V. Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1557411T1 (ko) * 2002-07-12 2013-01-31 Astellas Pharma Inc
KR101470115B1 (ko) 2013-01-09 2014-12-05 동국대학교 산학협력단 2-(페닐에티닐)티에노[3,4-b]피라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP6349464B2 (ja) * 2014-12-08 2018-06-27 ドングク ユニバーシティ インダストリー−アカデミック コーポレイション ファウンデーション 新規な４−（アリール）−Ｎ−（２−アルコキシチエノ［３，２−ｂ］ピラジン−３−イル）−ピペラジン−１−カルボキサミド誘導体及びその抗増殖効果

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052001A1 (en) * 1999-03-03 2000-09-08 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
WO2006054830A1 (en) * 2004-11-17 2006-05-26 Rexahn Pharmaceuticals, Inc. 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US8669256B2 (en) * 2010-05-28 2014-03-11 Merck Sharp & Dohme B.V. Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOLLI, S. K. ET AL.: "NaSH in the Construction of Thiophene Ring Fused with N-heterocycles: A Apid and Inexpensive Synthesis of Novel Small Molecules as Potential Inducers of Apoptosis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 18, 15 September 2014 (2014-09-15), pages 4460 - 4465, XP029053331 *

Also Published As

Publication number Publication date
US10059721B2 (en) 2018-08-28
KR101727412B1 (ko) 2017-04-17
WO2016093554A2 (ko) 2016-06-16
US20170320890A1 (en) 2017-11-09
KR20160070005A (ko) 2016-06-17
JP6349464B2 (ja) 2018-06-27
PL3231800T3 (pl) 2020-04-30
EP3231800A4 (en) 2018-05-30
EP3231800A2 (en) 2017-10-18
JP2018502070A (ja) 2018-01-25
HUE046316T2 (hu) 2020-02-28
EP3231800B1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
EP3473624A4 (en) NOVEL IMIDAZOPYRIDINE DERIVATIVE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER
WO2016109689A3 (en) Derivatives and methods of treating hepatitis b infections
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
EP3424928A4 (en) HETEROCYCLIC NITROGEN COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE
WO2016034946A3 (en) Thienopyrroles as histone demethylase inhibitors
MY179756A (en) Stabilized efinaconazole formulations
MX2018001324A (es) Forma cristalina de base libre de lorlatinib.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
HK1243424A1 (zh) 4'-硫代核苷的新型化合物及其製備方法、藥物組合物和應用
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
WO2016093554A3 (ko) 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과
EP3539951A4 (en) NOVEL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER AND INFLAMMATORY DISEASES
EP3069720A4 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
EP3710036A4 (en) STABLE ASCORBIC ACID COMPOSITIONS AND METHOD FOR THEIR USE
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
CN106687453A8 (zh) 作为溴结构域抑制剂的四氢喹啉衍生物
EP3239165A4 (en) Composition containing nitrogen heterocyclic hexapeptide precursor and preparation method and application thereof
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
EP3006434A4 (en) Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 15533076

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2017530301

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015867145

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15867145

Country of ref document: EP

Kind code of ref document: A2